You're scanning a medication list and see canagliflozin. And maybe you're a clinician double-checking a chart. Maybe you're a patient who just picked up a prescription and the pharmacist mentioned "some people shouldn't take this." Either way, you need the straight answer — not a copied package insert, not a vague "ask your doctor.
Here's the short version: canagliflozin isn't for everyone. And the list of who should avoid it is more specific than most summaries let on And that's really what it comes down to. No workaround needed..
What Is Canagliflozin
Canagliflozin (brand name Invokana) belongs to a class called SGLT2 inhibitors. That's why these drugs block a protein in your kidneys called sodium-glucose cotransporter 2. Normally, that protein reabsorbs glucose back into your blood. Block it, and you pee out the extra sugar. Blood glucose drops. Simple mechanism, real-world results.
This is the bit that actually matters in practice.
It's approved for type 2 diabetes — not type 1 — and also carries indications for reducing cardiovascular events in certain patients and slowing kidney disease progression in others. But the kidney connection is exactly where the contraindications start to matter.
How it differs from other diabetes meds
Unlike metformin or sulfonylureas, canagliflozin doesn't push your pancreas to make more insulin. That means its effectiveness depends entirely on kidney function. In practice, it doesn't make cells more sensitive to insulin either. It works downstream, at the kidney filter. When kidneys aren't filtering well, the drug can't do its job — and the risk profile shifts.
Why It Matters / Who Should Not Receive Canagliflozin
The FDA label is clear. So are clinical guidelines. But in practice, the "who should not take this" conversation often gets reduced to "bad kidneys." That's incomplete. Let's break it down properly Easy to understand, harder to ignore..
Severe renal impairment (eGFR below 30)
This is the big one. Canagliflozin is contraindicated when eGFR falls below 30 mL/min/1.Day to day, 73m². Not "use with caution." Not "reduce dose." Contraindicated.
Why? Practically speaking, two reasons. That's why first, the drug simply doesn't work well at that level of kidney function — there's not enough filtered glucose to excrete. Second, the safety data gets thin. On the flip side, the clinical trials that established its cardiovascular and renal benefits largely excluded patients below this threshold. Using it anyway means flying blind.
You'll probably want to bookmark this section.
And if a patient's eGFR drops below 30 while already on the drug? Still, current guidance says discontinue. Don't ride it out.
End-stage renal disease or dialysis
This follows logically from the above. If someone is on dialysis or has ESRD, their kidneys aren't filtering in any meaningful way. Canagliflozin has no mechanism to act. The label explicitly lists this as a contraindication.
History of serious hypersensitivity to canagliflozin
Anaphylaxis, angioedema, Stevens-Johnson syndrome — if a patient has had a true allergic reaction to this specific drug, don't rechallenge. Even so, cross-reactivity with other SGLT2 inhibitors is possible but not guaranteed. Still, most clinicians switch classes entirely rather than test it It's one of those things that adds up..
Type 1 diabetes
Canagliflozin is not approved for type 1 diabetes. Here's the thing — full stop. So using it off-label in T1D carries a real risk of euglycemic diabetic ketoacidosis — DKA with near-normal blood sugar. In real terms, that's a diagnostic trap. Patients feel sick, glucose looks "okay," and DKA gets missed until it's severe No workaround needed..
Active diabetic ketoacidosis
This should be obvious, but it's worth stating: don't start an SGLT2 inhibitor during active DKA. The drug can worsen ketogenesis. Treat the DKA first, reassess later.
Pregnancy (second and third trimesters)
Animal data shows renal developmental toxicity. Human data is lacking. The label recommends against use in the second and third trimesters. First trimester? Day to day, unclear. Most clinicians switch to insulin for the duration of pregnancy — it's the only glucose-lowering agent with a long, well-established safety profile in pregnancy Took long enough..
Breastfeeding
Canagliflozin shows up in rat milk. So the theoretical risk to a nursing infant's developing kidneys means the label recommends against it. Worth adding: no human lactation studies exist. Again, insulin is the standard alternative.
How It Works (and Why These Contraindications Exist)
Understanding the mechanism makes the contraindications intuitive rather than memorized.
The kidney filter dependency
Canagliflozin inhibits SGLT2 in the proximal tubule. Also, the drug has less substrate to work on. Here's the thing — this transporter handles about 90% of glucose reabsorption. But it only sees glucose that gets filtered at the glomerulus. If GFR drops, filtered glucose drops. Efficacy falls off a cliff around eGFR 30 Not complicated — just consistent..
The volume depletion link
By excreting glucose, you also excrete water osmotically. Mild diuresis. In healthy kidneys, this is trivial. In practice, in compromised kidneys — or patients on loop diuretics, or elderly patients with blunted thirst — it can tip into hypotension, acute kidney injury, or falls. That's not a contraindication per se, but it's why the next section matters.
The ketoacidosis mechanism
SGLT2 inhibitors lower insulin levels slightly (less glucose = less insulin demand) and raise glucagon. That shifts fuel metabolism toward fat oxidation and ketone production. In type 2 diabetes, this rarely causes trouble. In type 1, or during illness/surgery/starvation, it can trigger DKA — sometimes with only modest hyperglycemia Turns out it matters..
Common Mistakes / What Most People Get Wrong
"eGFR 45 is fine, right?"
Not automatically. Canagliflozin can be initiated down to eGFR 30 for certain indications (like CKD progression), but the glycemic efficacy is reduced. And if the indication is purely glucose lowering? That said, many guidelines suggest stopping or switching once eGFR drops below 45. The nuance gets lost in busy practice.
"It's just a water pill side effect"
The volume depletion risk is real, but it's not just a diuretic effect. SGLT2 inhibitors also affect tubuloglomerular feedback — they constrict the afferent arteriole slightly, lowering intraglomerular pressure. That's actually renoprotective long-term. But acutely, it can drop GFR. Even so, in a volume-depleted patient, that drop can be precipitous. Clinicians who treat it like a simple diuretic miss the hemodynamic piece That's the part that actually makes a difference..
Honestly, this part trips people up more than it should.
"All SGLT2 inhibitors have the same contraindications"
Mostly true, but not entirely. Empagliflozin and dapagliflozin have slightly different eGFR cutoffs for certain indications. Canagliflozin's amputation risk signal (seen in the CANVAS trial) is unique among the
class, influencing its labeling. While the amputation risk appears low in individual patients, it's a distinguishing factor in risk-benefit discussions Small thing, real impact. That's the whole idea..
Practical Clinical Approach
Pre-prescribing checklist
Before initiating canagliflozin, assess:
- Absolute contraindications (pregnancy, severe renal impairment)
- Volume status and concurrent diuretics
- History of falls or hypotension
- Recent illness, surgery, or steroid use
- Type 1 diabetes status
Monitoring protocol
Start low, go slow. Check eGFR and creatinine within 2-4 weeks of initiation and after any acute illness. Monitor for signs of volume depletion, especially in elderly patients. Educate patients about genital hygiene and early infection recognition Which is the point..
When to stop or switch
Hold the medication during acute illness, fasting, or major surgery. Consider discontinuation if eGFR drops below 30, or if patient experiences recurrent genital infections or unexplained hypotension.
Beyond the Basics
Cardiovascular protection
Despite glycemic limitations in advanced CKD, canagliflozin's cardiovascular benefits may persist. The EMPEROR and DAPA-CKD trials suggest renal protection extends beyond glucose control, though canagliflozin-specific data is still emerging.
Combination therapy considerations
Avoid combining with insulin in type 1 diabetes due to DKA risk. When used with other antidiabetics, monitor for additive effects on volume depletion.
Special populations
In elderly patients, start with careful volume assessment. In those with recurrent genital infections, consider topical antifungal prophylaxis rather than discontinuation. For patients with limited life expectancy, the renal benefits may not justify long-term use Small thing, real impact. Which is the point..
Conclusion
Canagliflozin represents a significant advance in diabetes management, offering both glycemic control and organ protection. On the flip side, its unique mechanism creates specific contraindications that extend beyond simple renal function thresholds. Successful prescribing requires understanding not just the "what" but the "why" behind each warning. By recognizing the interplay between glomerular filtration, volume homeostasis, and ketone metabolism, clinicians can better identify appropriate candidates while avoiding pitfalls that compromise patient safety. The key lies in patient selection, careful monitoring, and maintaining awareness that this medication's benefits are maximized when prescribed thoughtfully to the right individuals.
